A retrospective analysis was performed to modify our fourth-generation pharmacodynamic model for glucocorticoid receptor (GR) dynamics with incorporation
INTRODUCTION
Corticosteroids (CS) are widely used for the treatment of various inflammatory diseases, organ transplant patients, and as immunomodulatory agents (1, 2) . Severe metabolic side effects, including steroid-induced diabetes, muscle atrophy, and disorders in lipid metabolism (3, 4) , limit their therapeutic usefulness, especially with high-dose and long-term therapy. These actions of CS are predominantly generated by influencing the expression of diverse genes in numerous tissues. The regulation of gene expression by CS is mediated through the glucocorticoid receptor (GR) in target tissues.
Corticosteroids are protein-bound in plasma, predominantly associating with corticosteroid-binding globulin (CBG) and albumin (5) . After dissociation from its plasma protein carrier, CS enter the cell by passive diffusion (6, 7) and associate with heat-shock protein bound cytosolic GR, causing its dissociation from the heat-shock protein complex. Subsequently, the drug-receptor complex becomes activated, hyperphosphorylated and undergoes conformational changes (1, 8) . This activated drug-receptor complex translocates into the nucleus and binds to glucocorticoid response elements (GRE), specific DNA control regions (located at the 5 site) of the target gene, resulting in increased or decreased transcription of various mRNAs. This in turn results in translation to corresponding proteins and the specific physiological functions mediated by these proteins (9) . The drug-receptor complex dissociates from the GRE and returns to the cytosol where it may be either degraded or dissociated to recycle the free receptors which in turn may bind to a new ligand (10) . The glucocorticoids are also known to down-regulate their own receptors by a process called homologous down-regulation (11) . Activated drug-receptor complex in the nucleus is known to inhibit the transcription of GR mRNA (12) , thus further reducing the free cytosolic GR.
The effects of corticosteroids on the dynamics of free hepatic cytosolic receptor, receptor mRNA, and expression on target genes have been extensively studied in our lab. Mechanistic models were developed to capture the temporal patterns of receptor-mediated CS effects on various pharmacodynamic and pharmacogenomic (altered gene expression) markers (12) (13) (14) . In these earlier studies, we were technically limited to studying relatively few target genes at a time, such as the up-regulation of hepatic TAT mRNA and activity, hepatic phosphoenol-pyruvate carboxykinase (PEPCK) mRNA and activity (15) , glutamine synthetase (GS) mRNA and activity in the muscle (16) , and down-regulation of GR mRNA. However, in microarray experiments (17, 18) , where the effects of CS treatment were simultaneously examined for several thousands of genes, we (9) and Table II. encountered classes of rapidly up-or down-regulated genes which could not be described by our previous model. The nuclear drug-receptor complex (DR(N) in Fig. 1 ) which is assumed to mediate various pharmacogenomic effects of CS was not measured and was a calculated function. Previous models based on delayed gene effects of CS (TAT or GR mRNA) predicted that the concentration of DR(N) peaks about 2 hr following drug administration. Although simulated values of DR(N) could successfully be used as a driving force for up-regulation of later responsive genes, it could not explain CS modulation of genes which are upregulated extremely rapidly. For example, CEBP-β, a transcription factor gene which has a recognized GRE in its promoter region and is known to be modulated by CS showed an increase in transcription within minutes of drug administration with a peak at 1 hr. Although transrepression by CS is not as well-characterized as transactivation, down-regulated genes in our microarray dataset such as aldehyde dehydrogenase (ADH), showed similar rapid down-regulation by CS, which could not be described by the DR(N) function. The translocation of the steroid-receptor complex into the nucleus appears to be much faster than predicted by our earlier model. Various in vitro studies (10, 19) showed that 90% of steroid-bound receptors can enter the cell nucleus from the cytosol within 5 min of incubation with 10 nM of dexamethasone (DEX). Hence, the time, predicted for the complete translocation of the receptor complex from our earlier model, was a considerable overestimation. Keeping the basic structural model, we have modified several aspects of our previous receptor dynamic model by incorporating literature information available and applied this modified model to CS-induced changes in expression of a large number of genes obtained from microarray studies.
MATERIALS AND METHODS

Experimental
Acute Dosing Studies
Data for determining hepatic GR and GR mRNA dynamics were obtained from our previous studies (12, 20) . In brief, four groups of male adrenalectomized (ADX) Wistar rats were treated with MPL (SoluMedrol R , The Upjohn Company, Kalamazoo, MI) via jugular vein cannula. One group of rats received a single dose of 50 mg/kg of MPL at 0 hr (12) . In the second study three groups of rats received MPL at a single dose of 10 mg/kg at 0 hr, a single dose of 50 mg/kg at 0 hr, and dual doses of 50 mg/kg at 0 and 24 hr (20) . Animals (3-4 per time point) were sacrificed over a period of 72 hr for the single dose groups (0.25, 0.5, 0.75, 1, 2, 4, 5, 5. 5, 6, 7, 8, 12, 18, 24, 30, 36 , 48 and 72 hr) and over a period of 120 hr (0. 25, 1, 3, 5, 6, 7, 8, 12, 18, 24, 24.25, 25, 27, 29, 30, 31, 32, 36, 42 , 54, 72, 96 and 120 hr) for the dual dose group. Separate groups of control rats were used for these two studies; these rats received saline through the cannula and were sacrificed throughout the course of the study and used as the 0 hr time point for the biomarkers.
Chronic Dosing Study
Data for the receptor and its mRNA during chronic dosing were obtained from another study (21) . Two groups of male ADX Wistar rats were given 0.1 and 0.3 mg/kg/hr infusions of MPL using Alzet osmotic pumps (Model 2001, flow rate 1 µl/hr; Alza, Palo Alto, CA) subcutaneously implanted between the shoulder blades. Rats were sacrificed at various times up to 7 days (6, 10, 13, 18, 24, 36 48, 72, 96 and 168 hr). A control group of animals (n = 4) were implanted with saline-filled pumps and were sacrificed at various times throughout the 7-day study period.
For both the acute and chronic dosing studies, blood was collected, centrifuged, and the plasma was stored at −20 • C for the analysis of MPL. Livers were harvested, flash frozen with liquid nitrogen, and stored at −80 • C. Livers were ground to powder with a chilled mortar and pestle for further studies.
Microarray Study
The details of our microarray studies are published (17, 18) . Briefly, total RNA from rat liver was extracted using Trizol reagent according to manufacturer's protocols. RNAs were quantified spectrophotometrically and integrity was assessed by gel electrophoresis. RNA samples were stored at −80 • C. RNAs from individual rat livers were used to prepare the target and biotinylated cRNAs were hybridized to 47 individual Affymetrix GeneChips R Rat Genome U34A (Affymetrix, Inc.), containing 8799 probe sets. The values for each probe set on each chip were normalized to the mean of the four control values for that probe, which allowed us to assess the fold change of genes of interest after treatment.
Assays
Plasma concentrations of MPL were determined by a normal phase high-performance liquid chromatography (HPLC) method (22) . The lower limit of quantification is 10 ng/ml with inter-and intra-day assay variability less than 10%. A well-established radio-ligand binding assay was used to quantify the hepatic free cytosolic GR density. The total (D T ) and nonspecific (D NS ) binding of radio-labeled DEX were measured (12, 23) . The receptor density or B max at any given time point was calculated by simultaneously solving Eqs. (1) and (2) using the ADAPT II program (24)
where K D is the equilibrium dissociation constant for receptor binding, K NS is the non-specific binding constant and D f is the free drug available to bind to receptors. The variability (CV%) of this assay was less than 15%. The receptor density values were normalized by protein content of the cytosol preparation (25) . The GR mRNA was quantified by Northern hybridization (12, 26) . For each animal, triplicate determinations were done and the CV% was less than 12%.
Modeling of Receptor Dynamics
Pharmacokinetics
The PK of MPL from all studies were described by bi-exponential kinetics. For this analysis the PK of MPL was fixed using parameters (Table I ) from previous studies (12, 20 )
where C 1 and C 2 represent intercepts and λ 1 and λ 2 represent slopes. 
Receptor Dynamics
The model is based on the molecular mechanism by which CS are known to generate their genomic effects ( Fig. 1) . This model was applied to free cytosolic GR and its mRNA profiles.
MPL is known to bind to only albumin in the plasma yielding a stable protein-bound fraction of 0.77 for a wide range of total plasma concentrations (10-80,000 ng/ml) (27, 28) . Therefore, it was assumed that only 23% of the plasma total drug enters the cell to bind to their cytosolic receptors. Thus the free drug can be expressed as
where D t is the total MPL concentration in the plasma in nM (C t · 1000/374.4; MW of MPL: 374.4), where C t is expressed in terms of ng/ml and D f is the intracellular drug concentration (in nM). Since only the free drug can enter the cell by diffusion, it was assumed that the free drug (D f ) in the plasma binds to the hepatic free cytosolic receptor (R) forming the drug-receptor complex in the cytosol (DR). The DR then translocates into the nucleus of the cell forming DR(N) which is responsible for the down-regulation of GR mRNA by decreasing its synthesis. The dynamics of hepatic GR mRNA can be described by
where IC 50 Rm is the level of DR(N) responsible for 50% inhibition of the transcription rate (k syn,GRmRNA ) of GR mRNA; and k dgr,mRNA is the first-order degradation rate constant for the mRNA. Assuming that in the absence of drug the receptor mRNA baseline mRNA GR(0) is constant, k syn,GRmRNA can be expressed as
The free receptor in the cytosol, R, bound receptor, DR and DR(N), can be described as
where DR(N) is the drug bound receptor in the nucleus, k dgr,GR is the first-order degradation rate constant for GR, k on is the association rate constant for steroid receptor binding, k syn,GR is a translational constant which is proportional to GR mRNA. Similar to receptor mRNA, it can be assumed that the baseline GR is constant and therefore the translational rate constant k syn,GR can be expressed as
The values of the mRNA GR(0) and R 0 were obtained from Sun et al. (12, 20) and fixed for this analysis. The baseline values for DR and DR(N) are zero. In Eq. (9), k re is the overall turnover rate constant of DR(N) including the fraction (R f ) which is being recycled to form free R and the fraction (1 − R f ), degraded; k T is the first-order rate constant describing the translocation of DR to the nucleus. It has been reported that at the concentration of DEX equivalent to the intracellular concentration of MPL achieved even with the low-dose (10 mg/kg), the entry of DR in the nucleus is quite rapid after binding of steroid to its receptor; more than 90% of the bound receptor could potentially enter the nucleus within 5 min, which includes both the binding and the translocation process (10, 19) . Hence, the value of k T was fixed to 58.2 hr −1 ; considering nuclear translocation is complete within 5 min (7 t 1/2 ) to account for the rapid entry of DR to the nucleus.
The data from the high-dose, low-dose, and dual dose studies were fitted simultaneously to Eqs. (5)- (10) using ADAPT II (24) using the Maximum Likelihood method, where the variance model was
where Y represents the predicted value; σ 1 and σ 2 are the variance parameters which were fitted, and θ represents the structural parameters. The goodness of the fit was assessed by model convergence, visual inspection, Akaike Information Criterion (AIC), Schwarz Criterion (SC), estimator criterion value, and examination of residuals.
To check the predictability of our model, the parameters obtained from these fittings of receptor dynamics were used to simulate the mean and 95% confidence interval (CI) of the receptor time-profiles upon chronic dosing of MPL (at two infusion rates).
Array of Genomic Regulations by Nuclear Drug-Receptor Complex
Simulations were performed using indirect response (IDR) models (29) to describe a wide array of genomic responses that can be generated using DR(N) as the driving force
where mRNA s and mRNA I genes which are stimulated and inhibited upon CS administration, k syn is the zero-order production rate, k deg is the first-order loss rate for the respective mRNA, S sim is a linear stimulation constant, and IC 50sim is the concentration of DR(N) required to produce 50% inhibition of k syn . 
Modeling of Up-and Down-Regulated mRNA
The mRNA time profiles for hepatic TAT, CEBP-β, ornithine decarboxylase (ODC), argininosuccinate synthetase (ASS), aldehyde dehydrogenase (ADH), low density lipoprotein receptor (LDL-R), carbonic anhydrase (CA) and glutaminase mRNA from our microarray study (17, 18) from the high-dose group (50 mg/kg single dose) of MPL treated animals are examples of rapid and slow responding genes. Equation (12) was used to describe the increase in transcription of TAT, CEBP-β, ODC and ASS mRNA. Equation (13) was used for down-regulation in transcription of both ADH, LDL-R, CA and GA mRNA. In both cases DR(N) was used as the driving force to regulate transcription these genes. The mRNAs of interest, mRNA s , are produced with a zero-order transcription rate constant, k syn and degraded with the first-order rate constant, k deg . The baseline is
Since the signal from each chip was normalized by dividing by the mean of the signals from the control chips, the baselines for all mRNAs in the microarray dataset starts from 1. For some genes the baselines were estimated for improvement of model fitting. A piecewise approach was used for fitting the pharmacogenomic data. The PK of MPL was fixed in fitting the receptor dynamics from all dose levels. Subsequently all the PK and receptor parameters were fixed in fitting the mRNA profiles for all the up-and down-regulated genes used for fittings.
RESULTS
Pharmacokinetics
The simulated PK profiles for MPL are shown in Fig. 3a . The PK of MPL was described by bi-exponential kinetics for all dose levels. The half-lives of MPL for both the high-dose and the dual doses are approximately 30 min; however, for the 10 mg/kg dose the t 1/2 is 1.1 hr. Different parameter values were used for different dose levels (12, 20) , which are given in Table I .
Pharmacodynamic Analysis
GR mRNA
The observed steroid receptor mRNA dynamics after various doses of MPL are shown in Fig. 2 (top panel) along with mean and 95% CI of the model (Fig. 1) predictions. The drug causes down-regulation of the receptor mRNA at all dose levels. Variability in mRNA is apparent especially in the single low (10 mg/kg) and dual dose groups; however, most of the observed data fell within the 95% CI of model predictions. The model parameters could be estimated with reasonable precision (7-56%) ( Table II) . The baselines for the GR mRNA were different in rats from the different dose groups and were fixed for this analysis since estimation of the baselines did not improve the overall model fitting. The synthesis (k syn,GRmRNA = 1.96-3.2 fmol g −1 hr −1 ), and the degradation (k dgr,GRmRNA = 0.122 hr −1 , 24% variability), rate constants, for the GR mRNA are very similar to values from Sun et al. of 1.77-2.9 fmol g −1 hr −1 and 0.11 hr −1 (35% variability) (12, 20) . The present value of IC 50 Rm i.e. DR(N) required to cause 50% reduction in the GR mRNA was somewhat higher than previously reported, e.g. 26.2 (50 mg/kg single dose, CV% not reported) and 50.7 (dual and low-dose study, variability 63%) nmol/l/mg of protein compared to 123.7 nmol/l/mg protein (55.7% variability). However, considering the variability of these estimated parameter, they were not markedly different.
Receptor Dynamics
Observed hepatic cytosolic free GR density time profiles along with the model predictions are shown in Fig. 2 (bottom panel) from all acute dose groups. Since the protein binding of MPL (77%) was considered and only the free drug was assumed to interact with the receptor, the estimated value of k on (1.9 · 10 −2 nM −1 hr −1 , 47.8% CV) was somewhat higher (3.29 · 10 −3 nM −1 hr −1 , acute high-dose study, no CV% reported, 4.87 · 10 −4 nM −1 hr −1 , low and dual dose studies, 25% CV) than previously reported values (12, 20) . The free receptors from the cytosol disappear very rapidly after administration of the drug irrespective of the dose. However, for higher doses these levels remain suppressed for a longer period of time (4-5 hr) compared to the low-dose group where the receptor level begins to increase almost immediately. In both cases, biphasic return of receptors is apparent, which could partly be accounted for by receptor recycling and partly to de novo synthesis of receptor from its mRNA, since the slower return phase for the receptor parallels the return of the GR mRNA. At the end of the first rapid return phase (approximately 10 hr), receptors return to almost 40-50% of the baseline, which is somewhat lower than the estimated recycling factor, R f = 0.69 (95% CI: 0.59-0.79). This may imply that a portion of receptors undergo binding and recycling more than once. The second slower phase could be attributable to both receptor synthesis as well as recycling. The complete recovery of basal levels of receptors occurs at around 72 hr after both the 10 and 50 mg/kg doses.
DR and DR(N) Dynamics
Cell culture studies show that the disappearance of drug-bound receptor from the cytosol and its subsequent entry into the nucleus is very rapid (10, 19) . Therefore, the transfer rate constant k T was fixed to 58.2 hr −1 , which is equivalent to seven half-lives of the translocation rate. Whereas the cytosol to nuclear transfer of the steroid-receptor complex is quite rapid, the process of nuclear to cytosolic return is much slower (10) . This process was nicely captured by the simulated profiles for DR(N) from our model (Fig. 3) . Although the drug-bound receptor reached its maximum inside the nucleus within 5 min following MPL dosing, complete dissipation of this moiety from the nucleus required almost 10 hr. For the dual dose study, it can be observed that the free receptor levels in the cytosol do not return to the baseline before the second 50 mg/kg dose. Therefore, the subsequent formation of DR and DR(N) in the nucleus are lower after the second dose.
Chronic Dosing
Based on the parameters (with variability) obtained from the simultaneous fitting of the free cytosolic receptor and mRNA from all the single and dual-dosing studies, simulations were performed to predict the profiles (mean and 95% CI) after chronic dosing, which are shown in Fig. 4 . Both GR mRNA and free cytosolic receptors remain down-regulated for the entire time during the treatment. Our model was able to predict this behavior quite well, especially for the free cytosolic receptor profile. Similar to the acute dosing studies, much variability was evident in the GR mRNA profiles. The simulated profiles for the drug-receptor complex both in the cytosol and nucleus show an early rapid up-regulation; however, they eventually decline to a different steady-state than the baseline reflecting a new homeostasis.
Pharmacogenomic Modeling
Simulations shown in Fig. 5a,b show a wide range of responses that can be generated from our improved DR(N) profiles, with some genes being affected by the drug treatment much quicker than others based on their respective turnover rate constants. Particularly with the higher values of k deg (while IC 50sim or S sim remains constant) the response increases much faster than the lower values and thus could explain the variations in onset of responses for various genes. Further flexibility in the responses arise from differences is the ability of the drug to produce an effect, described by various stimulation or inhibitory constants (S sim or IC 50sim ). For the inhibitory responses it was assumed case that drug was able to cause maximum inhibition of the system (I max = 1). The mRNAs for CEBP-β, TAT, ODC and ASS showed up-regulation following 50 mg/kg MPL as depicted in Fig. 6 . Although these increases in transcription were evident within 15 min (except ASS) of drug exposure, the effect on CEBP-β mRNA (peaking at 1-2 hr) is much faster than TAT or ODC mRNA (peaking at 5-6 hr), and was latest for ASS mRNA (8-10 hr). This can be attributed to the difference in their loss rate constants, 0.047 hr −1 (40.6% CV) for ASS, 0.436 hr −1 (35.3% CV) for TAT mRNA compared to 1.66 hr −1 (28% CV) for CEBP-β. Stimulation constants (S DR(N) ) were comparable between CEBP-β and TAT, however, for ASS and ODC they were somewhat higher, perhaps due to the extent of stimulation that was induced by DR(N) compared to TAT and CEBP-β. It should be noted that extent of stimulation for ASS (∼2-fold from the baseline) was as high as for TAT (∼2-fold) or CEBP-β (∼3.5-fold), although the loss rate constant was much lower. Differences in k deg were seen for the down-regulated genes (Fig. 7) , i.e. 3.51 hr −1 (40.7% CV) for ADH, 1.88 hr −1 for LDL-R, 1.31 hr −1 for CA compared to a much lower value for GA, 0.139 hr −1 (11% CV), whereas the IC 50 sim values were closer. Thus we observed a more rapid downregulation for ADH, LDL-R and CA compared to GA. The DR(N) function derived from our model was able to capture all of these profiles adequately with reasonable precision for all estimated parameters (Tables III, IV) . Model convergence could not be achieved when attempts were made to use the previous model derived DR(N) to describe the rapidly up-or down-regulated genes. The present degradation rate constant for TAT mRNA (0.436 hr −1 , 35.3% CV) very closely resembled the value (0.383 hr −1 , 27.4% CV) estimated previously for the TAT mRNA profile obtained by Northern Hybridization (21) .
Discussion
For the past two decades, our laboratory has been involved in developing mechanism-based models of various receptor-mediated effects of corticosteroids. This report was aimed at modifying some aspects of our previous models for CS receptor dynamics. Our fourth-generation model (12, 20) for receptor dynamics was built based on treating ADX rats with various doses of MPL and examining effects on hepatic free cytosolic receptors and hepatic GR mRNA. It has been reported (1, 2, 8, 30 ) that most CS genomic effects are mediated by their drug-bound receptor dimer in the cell nucleus. Both the cytosolic (DR) as well as nuclear (DR(N)) drug-bound receptors, although they could not be quantitatively measured in any of our studies, are essential components of our mechanistic models. Thus in previous reports parameters associated with these two model compartments were based on the data available for the drug, its receptor, and the GR mRNA. The transduction compartment, DR(N), was used to model many CS driven effects, such as changes in hepatic TAT mRNA and activity (12, 14, 20, 21) , hepatic PEPCK mRNA and activity (15) , and many other genomic effects of CS (18) . Since these effects are generally of slow onset (i.e. peaks at 2 hr and later), the DR(N) peak, 2 hr post dose estimated from the fourth-generation model was able to capture the dynamics of most of these effects. However, this DR(N) profile was unable to explain drug effects on genes which are affected by CS much faster than 2 hr (e.g. CEBP-β mRNA, a transcription factor, known to have GC response element in its promoter region and which becomes up-regulated within 15 min after MPL treatment peaking at around 1 hr) or ADH mRNA, an enzyme mRNA reported to be influenced by CS treatment (31, 32) . This led us to investigate the kinetics of DR and DR(N) more carefully, i.e., how rapidly the receptor translocates from the cytosol to the nucleus of the cell once it is bound to its ligand. Many in vitro studies with rat glucocorticoid receptors monitoring the transfer of steroid receptors from the cell cytosol to the nucleus (10, 33, 34) showed that DEX binding resulted in the transfer of the drug-bound receptor to the nucleus is nearly complete (seven half-lives for 99% completion, k T ∼ 58.2 hr −1 ) within 5-10 min of steroid incubation. This transfer is both ligand-and concentration-dependent. The free MPL concentrations in the hepatic cells in our studies, even after of the low-dose (10 mg/kg), approximated about 1000 nM. This high concentration of MPL may trigger the cytosol-nuclear transfer of steroid receptor even faster than observed in the in vitro studies. Thus fixing the value of k T to 58.2 hr −1 allowed the DR(N) complex to form much faster than predicted by our previous model. Remaining parameters could be estimated with reasonable precision yielding good fittings of GR receptor density and mRNA data from all dose levels. However, this raised the question of the importance of k T on the outcome of the model fittings since use of different sets of k T values, i.e., 0.63 or 2.03 hr −1 from previous fittings (12, 20) or use of an in vitro value (58.2 hr −1 ) yielded comparable fittings of GR density and GR mRNA profiles. A sensitivity analysis revealed that changing the value of k T beyond 0.6 hr −1 does not change the predicted levels of GR density and GR mRNA significantly when other parameters are kept constant. On the other hand, varying k T beyond 0.6 hr −1 affects the dynamics of DR or DR(N) but only to 15 hr −1 , beyond which it does not allow any faster transfer from cytosol (DR) to the nuclear (DR(N)) compartment. Since the mechanism of action of genomic effects of CS indicates the presence of both DR and DR(N) compartments in the simplest case, we retained the basic structure of the model. However, due to the apparent insensitivity of the GR mRNA and GR density to higher values, k T was fixed to the in vitro values and the rest of the parameters were estimated. The PK parameters obtained from the previous studies were fixed for this analysis unlike the receptor dynamics which were fitted simultaneously from all dose levels. Although the PK of MPL apparently can be captured by bi-exponential kinetics, there are differences in half-lives between low and high doses. The PK of MPL shows dose-dependent changes in volume of distribution and apparent clearance along with reversible metabolism between methylprednisolone and its inactive metabolite methylprednisone in rats (35) . Thus for simplicity we used basic bi-exponentials as forcing functions to describe the PK after various doses of MPL. Determination of MPL in plasma (22) measures total plasma drug concentration, whereas only the free drug can enter the cell and bind to the receptor. In the previous studies (12, 20) , total MPL in the plasma was allowed to interact with the intracellular receptors, which perhaps resulted in an apparent binding constant, k on , which is somewhat lower (since the amount of cytosolic receptors are fixed) than the true value. Protein binding of MPL in rat plasma is linear since it only binds to albumin. Hence, use of the free fraction of the drug (0.23) allowed correction for a possible underestimation (∼10-fold lower) of the binding constant, k on , from previous studies. However, the k on estimated in our analysis is a combination of change in k t , subsequent change in R f , protein binding, and perhaps intracellular efflux and metabolism.
Although our comprehensive and mechanistic model describing steroid receptor dynamics was re-evaluated with protein binding of the drug and the rapid entry of the drug bound receptor into the nucleus, the overall model structure was not changed from the fourth- (12, 20) and fifth-generation models (14, 21) . Our modified model is highly flexible in describing both early and late responsive genes. Difficulties were obviated in achieving model convergence when the former DR(N) attempted fitting early responsive genes. This problem also prevented making statistical comparisons between the previous and current models. For the delayed effects, however, no significant improvement was observed for the newer model compared to the former one in terms of the usual model fitting criteria. The parameters associated with the genomic components were based on only the high-dose of MPL and one should be cautious when attempting to extrapolate these predictions to other dose levels.
The present model of receptor dynamics, however, is more mechanistically based and able to account for previous pharmacogenomic profiles (GS, TAT, and PEPCK) as well as for an enormous array of other genes which have been quantified using microarray methods. Profiles of thousands of genes altered by MPL in various rat tissues are available online (http://www.pepr.cnmcresearch.org).
